EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|June 20, 2014
Nonspecific Pruritic Rash: Your Dx?
A toddler from Nigeria, whose parents remained there ill with AIDS, presented with a fever and a widespread itchy eruption. Tests for HIV infection were positive. Which systemic etiologies can be ruled out when such an eruption presents?
Advertisement
A recently immigrated 18-month-old boy from Nigeria, whose parents remained there ill with AIDS, presented with a fever and a widespread presumably itchy eruption. Considering the family history, tests for HIV infection were obtained; the results were positive. The boy was observed vigorously scratching at rash-filled areas, establishing that the eruption was pruritic.
Which of the following systemic etiologies should NOT be considered when such an eruption presents?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
5 FDA Decisions for Primary Care to Know from September 2026
5